Windlas Biotech Limited Cash Flow Conversion Efficiency
Windlas Biotech Limited cash flow conversion efficiency. Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has a cash flow conversion efficiency ratio of 0.016x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs66.60 Million ≈ $720.25K USD) by net assets (Rs4.16 Billion ≈ $45.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Windlas Biotech Limited (2018–2025)
Cash flow conversion efficiency of Windlas Biotech Limited from 2018 to 2025. This chart illustrates how Windlas Biotech Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Windlas Biotech Limited stock price today for real-time trading data and today's change.
Windlas Biotech Limited Cash Flow Conversion Ratio Explained
Windlas Biotech Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Windlas Biotech Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Windlas Biotech Limited ranked by their cash flow conversion efficiency. Also see market value of Windlas Biotech Limited for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brogent Technologies
TWO:5263
|
-0.014x |
|
A Paradise Acquisition Corp.
NASDAQ:APAD
|
0.000x |
|
Quang Viet Enterprise Co Ltd
TW:4438
|
-0.156x |
|
TCI Express Limited
NSE:TCIEXP
|
0.026x |
|
Elanders AB (publ)
ST:ELAN-B
|
0.112x |
|
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
|
0.053x |
|
GTM Holdings Corp
TW:1437
|
-0.002x |
|
Iberpapel Gestion SA
MC:IBG
|
0.040x |
Annual Cash Flow Conversion Efficiency for Windlas Biotech Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Windlas Biotech Limited from 2018 to 2025. Review free cash flow generation of Windlas Biotech Limited to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs5.06 Billion ≈ $54.70 Million |
Rs681.87 Million ≈ $7.37 Million |
0.135x | -44.33% |
| 2024-03-31 | Rs4.50 Billion ≈ $48.66 Million |
Rs1.09 Billion ≈ $11.78 Million |
0.242x | +59.79% |
| 2023-03-31 | Rs4.02 Billion ≈ $43.50 Million |
Rs609.65 Million ≈ $6.59 Million |
0.152x | +555.31% |
| 2022-03-31 | Rs3.95 Billion ≈ $42.69 Million |
Rs91.30 Million ≈ $987.37K |
0.023x | -59.80% |
| 2021-03-31 | Rs1.99 Billion ≈ $21.53 Million |
Rs114.54 Million ≈ $1.24 Million |
0.058x | -51.77% |
| 2020-03-31 | Rs2.10 Billion ≈ $22.67 Million |
Rs250.06 Million ≈ $2.70 Million |
0.119x | +23.77% |
| 2019-03-31 | Rs1.94 Billion ≈ $20.94 Million |
Rs186.54 Million ≈ $2.02 Million |
0.096x | -59.28% |
| 2018-03-31 | Rs1.25 Billion ≈ $13.52 Million |
Rs295.91 Million ≈ $3.20 Million |
0.237x | -- |
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more